Antitrust

• ADM: European Commission investigates ADM
• ADM: How Long will investigation cripple management?
• ADM: Judge to Dismiss Lawsuit after 6 years
• ADM’s Antitrust War Sputters Toward Conclusion
• American Airlines documents prove predatory pricing
• Biomet, Inc. (“BMET”): Betting Too Much on Appeal
• Bromide Investigation
• CANAL+ vs. NDS GROUP
• Great Lakes Chemical’s CEO Is a Whistleblower!!
• Microsoft has put its foot in its mouth
• Microsoft: What happens when Microsoft loses?
• Microsoft: Why Justice Changed to Monopolization
• Microsoft: Will “the Remedy” Help Competitors?
• Microsoft: without criminal antitrust charges, no threat
• Microsoft’s Findings of Fact will be harsher than expected
• UCAR: Price-Fixing Fine of $110 million
• WSJ: Justice Dept. Plans to Appeal AMR Antitrust Case

Class Actions

• Avery vs. State Farm
• Avery vs. State Farm: Consumer class actions restricted
• Breast Implants: Dow Chemical or Corning will pay
• Humana class action may change HMO coverage
• If MCK’s 2nd Amended Complaint dismissed, costs fall
• Interpublic Group’s Securities Litigation
• MCK’s inadequate merger proxy: restated earnings likely
• Merrill Lynch Orange County
• TAPS shareholders sue Caremark (MedPartners)
• VISX Anti-Trust Class Actions Pose No Material Risk

FDA

• BMY “Consents” to Improper Orange Book Listings
• AAI’s Prosac & Prilosec Patents & Buspar Delisting
• BuSpar: Will FDA list BMY new Buspar patent ?
• Hatch Waxman Act #1
• Hatch Waxman Act #2
• Hatch Waxman Act #3
• Prozac: New rule threatens Barr Labs 180 day exclusivity
• Schering Plough resolves FDA issues
• Schering Plough’s GMP Troubles with the FDA
• Taxol 1: Why did ABI to list 331 in the Orange Book?
• Taxol 2: Can Ivax to launch its generic Taxol?
• Taxol 3: Has Bristol Myers cut a deal with Napro?
• Taxol 4: Can FDA issue ANDAs to Mylan & Zenith
• Taxol 5: NaPro and Abbot sue Mylan

Fraud

• Columbia/HCA 1: Healthcare Corporation
• Columbia/HCA 2: Settlement Talk Rumors
• Columbia/HCA 3: Jury Hears Criminal Fraud Evidence
• Columbia/HCA 4: Guilty Pleas Resolve Criminal Probe
• Columbia/HCA 5: Court Reinstates Shareholder Suit
• Rite Aid may face more suits for surcharges to uninsured
• Standard & Poors sued by Abu Dhabi Bank

Mass Tort Cases

• AHP 1: Stock rise ignores the fen-phen litigation
• AHP 2: Punitive damages awarded in Diet Drug Cases
• AHP 3: Diet drug settlement costs continue to rise
• AHP 4: Fen-phen reservers were consistently low
• AHP 5: Fen-phen, The $22 Billion Gold Rush
• Asbestos I: Executive Summary
• Asbestos II: Litigation
• Asbestos III: “Premises Defendants” Under-Reserved
• Asbestos IV: Conspiracy Theory in Asbestos Litigation
• Asbestos V: Bankrupt Defendants
• Asbestos VI: Settlements Rejected by Supreme Court
• Asbestos VII: McDermott Responds to Plaintiffs Lawyers
• Asbestos VIII: WR Grace Mergers failed to avoid liability
• Baycol Report: A Primer on Mass Tort Drug Cases
• Baycol: Bayer Names New Chief Executive
• Tobacco 1: Liggett’s Settlement Pressures Industry
• Tobacco 2: Settlement Talks Led by Bible and Goldstone
• Tobacco 3: Boston Globe Indicates the Deal is Done
• Tobacco 4: Verdict predicted settlement in December ’96
• Tobacco 5: Settlements in FL, MS, TX, & MN
• Tobacco 6: the ’98 elections may delay settlement

Mergers

• Boeing McDonnell Douglas Merger
• Boeing: EU threatens Boeing-McDonnell Douglas merger
• FTC: Courts will approve Staples/Office Depot Merger
• Pfizer, Warner Lambert, and now P&G
• Will Justice block airline & telephone mergers?
• WSJ: Court Approves AMR’s Bid To Buy TWA
• WSJ: United & US Air May End $4.3 Million Merger

Noteworthy Decisions

• AHP 4: Fen-phen reserves were consitently low
• BP CEO Resigns over Propane
• Grace reverse mergers failed to avoid asbestos liability
• Maytag-Whirpool Merger
• Prilosec: Andrx predicted to lose when stock was $55
• Valassis: Judge will deny Murdock’s new trial motion

Patent Infringement Drugs

• Adderal XR Claims Construction: Shire, Impax & Barr
• Adderall XR: Shire Shares Rise on Settlement With Barr
• Augmentin 1: Early Ruling Favors Generics
• Augmentin 2: Federal Trial Judge splits decision
• Claritin 1: Judge likely to deny Summary Judgment
• Claritin 2: Schering Plough loses Claritin Patent Protection
• Levaquin®: JNJ likely to prevail against Mylan
• Levaquin®: as predicted, the Court Bars Mylan’s launch
• Neurontin 1: Interim Status Report
• Neurontin 2: Generic Competition likely in September ‘02
• Norvasc: Federal Circuit will reverse trial & rule for Pfizer
• Paxil 1: Glaxo’s Patents Appear Safe Until at least 2006
• Paxil 2: Invalidation of UK patents will not impact US cases
• Plavix® Should Survive Generic Attack until 2011
• Prozac: Verdict reverses: Barr Labs will win
• Taxus Stent Launch by Boston Scientific to be Delayed
• Wellbrutrin: Can Glaxo enjoin Andrx during appeal
• Wellbutrin® – Glaxo likely to reverse of Andrx decision

Patents

• AVANT! v. Cadence
• Digital v Intel Settlement Looms
• Digital v. Intel: Preliminary Injunction is Highly Unlikely
• Farm v Pioneer: Will Supreme Ct. Uphold Plant Patents?
• Intergraph v Intel
• Micron Technology and Hyundai sue Rambus
• Rambus sues Hyundai in ITC
• Rambus: SDR and DDR Patents
• Rambus’ vs. Infineon

Product Recalls

• Benlate Update
• Benlate Update
• Benlate: $1 billion+ to Settle & $100 million+ in Fines
• Benlate: Dupont terminates future sales
• Boeing Announces Retrofit
• Boeing: 737 Rudder Exposes to Damages or Grounding

Tax

• Canadian Income Trusts: Tax Likely to Pass Soon
• Filed Rate Doctrine Would Preempt California PUC
• Pipeline MLPs Will Lose Income Tax Allowance in ROE

Trials

• Duragesic© — JNJ likely to lose to Mylan Labs
• Epogen 1: TKT’s Malpractice Weakens Defense
• Epogen 2: summary judgement motions continued
• Epogen 3: Only a Miracle Can Save TKT !
• Epogen 4: Appeals Court Confirms Amgen Win
• Fosamax Weekly: Merck Retains Exclusivity until 2018
• Fosamax® Daily: Appeals Court Will Rule for Merck
• Fosmax Daily: Merck will retain exclusivity until 2007
• Fosmax: Courts Uphold Merck’s Daily & Weekly patents
• Lipitor Patents Upheld by Federal Trial Judge
• Lipitor Summary: Ranbaxy likely to prevail
• Lipitor Trial Day 1: Pfizer v. Ranbaxy
• Lipitor Trial Day 2: Pfizer v. Ranbaxy
• Lipitor Trial Day 3: Pfizer v Ranbaxy
• Lipitor Trial Day 4: Pfizer v. Ranbaxy
• Lipitor’s Patent Upheld by Appeals Court
• Prilosec Astra Zeneca’s Case in Chief Trial Days 1-13
• Prilosec Trial Day 13
• Prilosec Trial Day 14
• Prilosec Trial Day 15-19
• Prilosec Trial Day 20
• Prilosec Trial Day 21
• Prilosec Trial Day 22
• Prilosec Trial Day 23
• Prilosec Trial Day 24
• Prilosec Trial Days 25 & 26
• Prilosec Trial Days 27-30
• Prilosec Trial Days 31-34
• Prilosec Trial Days 35-38
• Prilosec Trial Days 39-41
• Prilosec: Judge Rules Andrx Infringed
• Valassis News Corporation vs. News Corporation
• Valassis settles for $500 million